Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.
Jonathan Trent, MD, PhD on Phase I Study of the Mutant IDH1: Can Patients be Treated with Ivosidenib? @JTrentMDPhD @SylvesterCancer
